QoL improved or was maintained with Kisqali in M7 and M3, do we have any evidence of this? Dr. Elisabetta Munzone is speaking on "QoL improved or was maintained with Kisqali in M7 and M3, do we have any evidence of this?" Kisqali Channel 00:02:49
ESMO 2020: Dr. Peter Fasching: Ribociclib vs Palbociclib MAIC analysis Dr. Peter Fasching speaking on "Ribociclib vs Palbociclib MAIC analysis" ESMO 00:04:11
Talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali ? Dr. Joanna Kufel-Grabowska is discussing on "When talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali?" Kisqali Channel 00:03:08
ESMO 2020: Dr. Sara Hurvitz: Ribociclib and resistance to prior ET in the M3 and M7 Dr. Sara Hurvitz is speaking on "Ribociclib and resistance to prior ET in the M3 and M7". ESMO 00:02:49
ESMO 2020: Dr. Michelino De Laurentiis: Ribociclib dose reduction on OS in M3 and M7 Dr. Michelino De Laurentiis is speaking on "Ribociclib dose reduction on OS in M3 and M7." ESMO 00:03:49
Key takeaways from NEJM 12/2019 ML3 OS data Dr. Peter Fasching is discussing the key takeaways from NEJM 12/2019 ML3 OS data. Kisqali Channel 00:01:35
